Royal Society of Chemistry, RSC Medicinal Chemistry, 6(13), p. 731-736, 2022
DOI: 10.1039/d2md00064d
Full text: Unavailable
Novel BRAFV600E PROTACs were developed that maintain target degradation while sparing paradoxical activation of the MAPK pathway in BRAFwt cells.